| Amryt Pharma is a biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from serious and life-threatening rare disease. Co.'s commercial business comprises two orphan disease products: JUXTAPID®/ LOJUXTA® (lomitapide), which is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia; and MYALEPT® / MYALEPTA® (metreleptin), which is approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. We show 1 historical shares outstanding datapoints in our AMYT shares outstanding history coverage, used to compute AMYT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AMYT market cap history over the course of time is important for investors
interested in comparing AMYT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AMYT versus a peer is one thing; comparing
AMYT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AMYT can fluctuate over the course of history.
With this page we aim to empower investors researching AMYT by allowing them to research the AMYT market cap history.